US equities |
SPCX $173.98 ▲+1.69% NVDA $241.90 ▲+1.25% MU $1,064.70 ▲+0.07% AMD $657.24 ▲+4.03% MRVL $292.52 ▲+7.84% SNDK $1,674.33 ▼-1.75% AVGO $378.73 ▲+4.47% TSLA $380.37 ▲+0.43%
FinancialContent

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.69 +0.09 (+0.73%)
Delayed Quote Updated: 11:21 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathfinder Limited
Via Business Wire
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
News headline image
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
From Compass Pathfinder Limited
Via Business Wire
News headline image
Why Compass Pathways Stock Was a Double-Digit Winner This Week ↗
Via The Motley Fool
News headline image
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathways plc
Via Business Wire
More People are Microdosing Psychedelics to Ease the Challenges of Parenting
Via Investor Brand Network
News headline image
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways to Participate in Stifel Virtual CNS Forum
From Compass Pathways plc
Via Business Wire
US Embassy Tells Americans to Desist from Using Ayahuasca in Peru
Via Investor Brand Network
Topics Law Enforcement
News headline image
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish ↗
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier. 
Via Stocktwits
News headline image
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says ↗
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026. 
Via Benzinga
News headline image
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript ↗
CMPS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
This Plumas Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
From Compass Pathways plc
Via Business Wire
News headline image
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
From Compass Pathways plc
Via Business Wire
Washington State Bills Seek to Legalize Psychedelics for Therapeutic Use
Via Investor Brand Network
News headline image
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
From Compass Pathways plc
Via Business Wire
News headline image
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months ↗
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca. 
Via Stocktwits
News headline image
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. ↗
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >